Skip to main content
Article
Probiotics: Finding the Right Regulatory Balance
Faculty Scholarship
  • Diane E. Hoffmann, University of Maryland Francis King Carey School of Law
  • Claire M. Fraser-Liggett, University of Maryland School of Medicine, Institute for Genome Sciences
  • Frank B. Palumbo, University of Maryland School of Pharmacy
  • Jacques Ravel, University of Maryland School of Medicine, Institute for Genome Sciences
  • Karen H. Rothenberg, University of Maryland Francis King Carey School of Law
  • Virginia Rowthorn, University of Maryland Francis King Carey School of Law
Document Type
Article
Publication Date
10-18-2013
Keywords
  • Human Microbiome Project,
  • HMP,
  • biologics,
  • regulation
Comments

This is the authors' version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Policy Forum, vol. 342, October 18, 2013. see: http://www.sciencemag.org/content/342/6156/314.full?ijkey=QUF.p5J3snuso&keytype=ref&siteid=sci

DOI: 10.1126/science.1244656

Abstract

Some products marketed as drugs should be excused from Phase I trials, but safety and efficacy claims for dietary supplements should be more tightly regulated.

Journal
342 Science 6156 (2013)
Citation Information
342 Science 6156 (2013).